Breakthrough research reveals that facial ageing is improved significantly with unique RecoSMA® technology

LONDON, UNITED KINGDOM, August 19, 2016 /EINPresswire.com/ -- RecoSMA® is a unique & revolutionary method to repair damaged human tissue. The objective of the study was to determine the efficacy and safety of a new method of facial rejuvenation using a 2940-nm Er:YAG laser with Spatially Modulated Ablation - SMA. A pilot study was performed on 16 women with moderate to severe signs of facial ageing relative to chronological age and who underwent two treatment sessions with an Er:YAG laser coupled with the revolutionary RecoSMA® technology. Mario A. Trelles, M.D Ph.D (1) and Vladimir Khomchenko (2) performed the research which was recently published in an edition of Lasers in Medical Science (3).

Method: The trial was predetermined based on previous experience with the technology for skin rejuvenation. A heterogeneous group of 16 women, with skin phototypes I–IV, was selected. The inclusion criteria was age between 35 and 70 years, moderate to severe signs of facial ageing relative to chronological age, acceptance of the terms and conditions for active participation, and commitment to the follow-up phases of the study. Two treatment sessions were carried out, with an interval of 3 weeks. The interventions were performed by a single physician, specifically trained to perform the procedure and who did not take part in the evaluation of the results. To evaluate the clinical and histological results, photographs and biopsies were taken before the first treatment session and 3 months after the second treatment session. Procedure during the treatment:the nozzle of the SMA module was placed on the skin surface, and the laser was pulsed at 3 Hz, with a 50% overlap. A fluence of 3.2 J/cm2 was used to treat fine lines (wrinkles of grades I and II), and a fluence of 4.6 J/cm2 was used to treat more aged skins with more pronounced wrinkles (grades III and IV).

Clinical results: Fine lines, wrinkles and overall facial ageing improved significantly showing the disappearance or reduction of fine lines and wrinkles, improvement in skin texture, tightening of loose skin, minimisation of sallowness, and reduction of uneven pigmentation. All patients completed the study and presented no significant side effects or complications.

Conclusion: After showing the patients the comparative photographs before and after treatment, 75% of women stated that they were satisfied or very satisfied and would recommend the treatment. Preliminary results show an excellent safety & efficacy profile for this technology, which, based on observed results, can be considered to have advantages over other current methods of facial rejuvenation.

Dr Trelles further added “… When I tried the Multiline laser for the first time, I was very impressed, first of all, because this is not just a single laser but rather a universal laser platform which makes it possible to work with different laser emitters. In addition to its polyfunctionality, I would like to point out the built-in functional treatment methods. At this time, the most important aspects for physicians are the treatment methods’ safety and the post-treatment recuperation time. This laser is safe – it lets the patients resume their normal routine very quickly, which is a great advantage…”

LINLINE (http://www.linline.com) is an international manufacturer of high quality medical laser devices for aesthetic, dermatological and surgical purposes.

SOURCE Linline Medical Systems SAS



1.Dr Mario A. Trelles is internationally renowned for his expertise and contributions to laser advancements in medicine and surgery. He has held executive positions at numerous professional medical organisations, including past terms as President of the European Laser Association (ELA)

2.Vladimir Khomchenko is a Research Scientist, Head of R&D, CEO at LINLINE Medical Systems

3.Lasers Med Sci DOI 10.1007/s10103-016-2010-z24 June 2016# Springer-Verlag London 2016

A.Troshkin
Linline Medical Systems
+44(0)774-RECOSMA
email us here